ACC 2026: Lorundrostat Lowers BP but Raises Hyperkalemia Risk

Why It Matters

The blood‑pressure reductions are clinically meaningful, offering a new option for resistant hypertension, but the elevated hyperkalemia risk could limit adoption unless robust monitoring and patient‑selection protocols are implemented.

Key Takeaways

• Lorundrostat 100 mg cuts systolic BP ~11 mm Hg.
• 50 mg dose lowers systolic BP ~9 mm Hg.
• Both doses raise hyperkalemia risk, higher at 100 mg.
• Meta‑analysis pooled 1,060 patients from three trials.
• Future use hinges on monitoring and patient selection.

Pulse Analysis

Resistant hypertension remains a major therapeutic challenge, affecting roughly 10‑15 % of patients despite three‑drug regimens. Aldosterone excess drives sodium retention and vascular remodeling, prompting guidelines to recommend mineralocorticoid receptor antagonists (MRAs) such as spironolactone. However, MRAs are frequently curtailed by hyperkalemia and declining renal function, especially in older adults or those with chronic kidney disease. This safety ceiling has spurred interest in upstream approaches that suppress aldosterone synthesis rather than block its receptor, a niche where selective aldosterone synthase inhibitors could theoretically deliver efficacy with improved tolerability.

The ACC‑presented meta‑analysis pooled 1,060 participants from three randomized, placebo‑controlled studies and showed that lorundrostat delivers dose‑dependent blood‑pressure reductions—9 mm Hg systolic at 50 mg and 11 mm Hg at 100 mg—accompanied by modest diastolic declines. These figures compare favorably with the average 8‑10 mm Hg drop seen with high‑dose MRAs, suggesting lorundrostat can meaningfully augment existing regimens. Yet the safety signal cannot be ignored: hyperkalemia events rose in both dose groups, with a steeper increase at the higher dose, echoing the very risk that MRAs aim to avoid.

From a commercial perspective, lorundrostat is likely to be positioned as a late‑line add‑on for patients who have exhausted conventional agents, rather than a first‑line alternative. Successful market entry will depend on clear risk‑mitigation protocols, point‑of‑care potassium monitoring, and differentiation from inexpensive generic MRAs. Ongoing phase III trials will need to demonstrate sustained efficacy, renal safety, and cost‑effectiveness, particularly in high‑risk cohorts such as those with chronic kidney disease. If these hurdles are cleared, lorundrostat could carve out a niche in resistant hypertension algorithms, but without a safety advantage its uptake may remain limited.